These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 34920938)

  • 1. Efficacy and safety of anti-sclerostin antibodies in the treatment of osteoporosis: A meta-analysis and systematic review.
    Poutoglidou F; Samoladas E; Raikos N; Kouvelas D
    J Clin Densitom; 2022; 25(3):401-415. PubMed ID: 34920938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of Romosozumab in treatment for low bone mineral density: a systematic review and meta-analysis.
    Kaveh S; Hosseinifard H; Ghadimi N; Vojdanian M; Aryankhesal A
    Clin Rheumatol; 2020 Nov; 39(11):3261-3276. PubMed ID: 32385757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A systematic review and meta-analysis of efficacy and safety of Romosozumab in postmenopausal osteoporosis.
    Singh S; Dutta S; Khasbage S; Kumar T; Sachin J; Sharma J; Varthya SB
    Osteoporos Int; 2022 Jan; 33(1):1-12. PubMed ID: 34432115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of teriparatide versus alendronate for treatment of postmenopausal osteoporosis: A meta-analysis of randomized controlled trials.
    Wang YK; Qin SQ; Ma T; Song W; Jiang RQ; Guo JB; Li K; Zhang YM
    Medicine (Baltimore); 2017 May; 96(21):e6970. PubMed ID: 28538396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Romosozumab in postmenopausal women with low bone mineral density.
    McClung MR; Grauer A; Boonen S; Bolognese MA; Brown JP; Diez-Perez A; Langdahl BL; Reginster JY; Zanchetta JR; Wasserman SM; Katz L; Maddox J; Yang YC; Libanati C; Bone HG
    N Engl J Med; 2014 Jan; 370(5):412-20. PubMed ID: 24382002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative efficacy of bone anabolic therapies in women with postmenopausal osteoporosis: A systematic review and network meta-analysis of randomized controlled trials.
    Hernandez AV; Pérez-López FR; Piscoya A; Pasupuleti V; Roman YM; Thota P; Herrera A
    Maturitas; 2019 Nov; 129():12-22. PubMed ID: 31547908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the efficacy and safety of romosozumab (evenity) for the treatment of osteoporotic vertebral compression fracture in postmenopausal women: A systematic review and meta-analysis of randomized controlled trials (CDM-J).
    Huang W; Nagao M; Yonemoto N; Guo S; Tanigawa T; Nishizaki Y
    Pharmacoepidemiol Drug Saf; 2023 Jun; 32(6):671-684. PubMed ID: 36703260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blosozumab in the treatment of postmenopausal women with osteoporosis: a systematic review and meta-analysis.
    Su Y; Wang W; Liu F; Cai Y; Li N; Li H; Li G; Ma L
    Ann Palliat Med; 2022 Oct; 11(10):3203-3212. PubMed ID: 36367007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Romosozumab versus Teriparatide for the Treatment of Postmenopausal Osteoporosis: A Systematic Review and Meta-analysis through a Grade Analysis of Evidence.
    Tian A; Jia H; Zhu S; Lu B; Li Y; Ma J; Ma X
    Orthop Surg; 2021 Oct; 13(7):1941-1950. PubMed ID: 34643048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost effectiveness of romosozumab versus teriparatide for severe postmenopausal osteoporosis in Japan.
    Hagino H; Tanaka K; Silverman S; McClung M; Gandra SR; Charokopou M; Adachi K; Johnson B; Stollenwerk B
    Osteoporos Int; 2021 Oct; 32(10):2011-2021. PubMed ID: 33772328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-sclerostin antibodies: utility in treatment of osteoporosis.
    Clarke BL
    Maturitas; 2014 Jul; 78(3):199-204. PubMed ID: 24842796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.
    Stevenson M; Jones ML; De Nigris E; Brewer N; Davis S; Oakley J
    Health Technol Assess; 2005 Jun; 9(22):1-160. PubMed ID: 15929857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Romosozumab: A Review in Postmenopausal Osteoporosis.
    Paik J; Scott LJ
    Drugs Aging; 2020 Nov; 37(11):845-855. PubMed ID: 32909197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Romosozumab increases bone mineral density in postmenopausal Japanese women with osteoporosis: A phase 2 study.
    Ishibashi H; Crittenden DB; Miyauchi A; Libanati C; Maddox J; Fan M; Chen L; Grauer A
    Bone; 2017 Oct; 103():209-215. PubMed ID: 28687496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Teriparatide versus Salmon Calcitonin Therapy for the Treatment of Osteoporosis in Asia: A Meta-analysis of Randomized Controlled Trials.
    Chen C; Alqwbani M; Zhao J; Yang R; Wang S; Pan X
    Endocr Metab Immune Disord Drug Targets; 2021; 21(5):932-942. PubMed ID: 33109070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
    Gallagher JC; Rosen CJ; Chen P; Misurski DA; Marcus R
    Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative efficacy and safety of pharmacological interventions for osteoporosis in postmenopausal women: a network meta-analysis (Chongqing, China).
    Tan X; Wen F; Yang W; Xie JY; Ding LL; Mo YX
    Menopause; 2019 Aug; 26(8):929-939. PubMed ID: 31021904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-sclerostin - is there an indication?
    Larsson S
    Injury; 2016 Jan; 47 Suppl 1():S31-5. PubMed ID: 26768288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status.
    Langdahl BL; Marin F; Shane E; Dobnig H; Zanchetta JR; Maricic M; Krohn K; See K; Warner MR
    Osteoporos Int; 2009 Dec; 20(12):2095-104. PubMed ID: 19350340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Romosozumab: A Novel Injectable Sclerostin Inhibitor With Anabolic and Antiresorptive Effects for Osteoporosis.
    Nealy KL; Harris KB
    Ann Pharmacother; 2021 May; 55(5):677-686. PubMed ID: 32862655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.